Impact of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older

Impact of the Implementation of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older

The primary objective of this study is to evaluate the impact of the implementation of collaborative pharmaceutical care on drug support at admission for patients 65 years of age and older.

This is a cluster-randomized study with a stepped-wedge design. Clusters correspond to participating centers. A randomly selected center is crossed-over into the intervention every fifteen days after the start of inclusions.

The secondary objectives are to evaluate:

A. The potential and observed clinical impact of the implementation of collaborative pharmaceutical care.

B. The acceptance rate of pharmaceutical interventions during collaborative pharmaceutical care.

C. Avoidable costs related to the consumption of care generated by the occurrence of serious adverse drug reactions.

D. The satisfaction of health professionals concerning the transfer of information on the patient's drug therapy carried out as part of collaborative pharmaceutical care.

Inclusion Criteria:

• The patient or his/her legal representative was informed about the study
• The patient is admitted as an in-patient to one of the participating hospitals
• The patient is available for 3 months of follow-up

Exclusion Criteria:

• The subject is participating in another drug study
• The subject is under judicial protection
• It is impossible to correctly inform the patient or his/her legal representative
• The patient or his/her legal representative refuses to participate in the study
• The expected life span of the patient is less than the required 3 months of follow-up
• It is impossible to contact the patient after hospitalisation
• Hospitalizatin for longer than 21 days